Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 8 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.12 [0.01, 2.21]
1 study · 55 participants
Low

Clinical response · Patients with collagenous colitis

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.82 [1.13, 2.93]
1 study · 55 participants
Low

Histological response · Patients with collagenous colitis

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 1.97 [1.24, 3.13]
1 study · 55 participants
Low

Adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.69 [0.43, 1.1]
1 study · 55 participants
Low

Withdrawals due to adverse events · Patients with collagenous colitis

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.65]
1 study · 55 participants
Low

Clinical response · patients with active lymphocytic colitis

Budesonide may leads to higher clinical response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.03 [1.25, 3.33]
2 studies · 57 participants
Low

Histological response · patients with active lymphocytic colitis

Budesonide may leads to higher histological response compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 2.44 [1.13, 5.28]
2 studies · 39 participants
Low

Adverse events · patients with active lymphocytic colitis

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

1 finding from 1 review

Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.59]
1 study · 42 participants
Low